Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ludwig Oxford’s Xin Lu shows an unexpected suppression of KRAS and inflammation driven pancreatic cancer by the p53 suppressor iASPP.

Tumour suppressor p53 is mutated in around 50% of human cancers and work is carried out to understand how p53 loses its tumour suppressive ability in tumours containing wild-type p53. In working to understand this concept, Paul Miller and colleagues have discovered that iASPP (inhibitor of Apoptosis Stimulating Protein of p53) is a suppressor of both inflammation and pancreatic cancer (PC) initiation.

The Lu laboratory identifies iASPP as a paradoxical suppressor of oncogenic KRAS-driven tumorigenesis and inflammation. The group investigated the ability of iASPP to regulate the pancreatic inflammatory response and PC formation. iASPP was found to suppress pancreatic cancer onset driven either by oncogene KRAS or by a combination of oncogenic KRAS and p53 – showing that it can suppress PC initiation independent of p53.

Read the full paper in Cell Death and Differentiation journal.

Similar stories

Vacancy: Postdoctoral Researcher - Hypoxia signalling in tumour microenvironment control

Grade 7: £36,024 - £44,263 with a discretionary range to £48,350 p.a.